American Association for the Advancement of Science, Science Translational Medicine, 530(12), 2020
DOI: 10.1126/scitranslmed.aay8329
Full text: Unavailable
Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy.